αααααβααΎαNBIX β’ NASDAQ
add
Neurocrine Biosciences Inc
125.39$
αααααααααα(0.00%)0.00
125.39$
ααΆααα·αα 6 αα·αα»ααΆ, 8:00:00 PM ααααβααα -4 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·αααΆαααΈααααΆααααΆααααααΆααα
α’αΆαααα·α
αα·αααΈαα»α
124.61$
α
αααααααααααα
124.08$ - 126.81$
α
ααααααα½αααααΆαα
α»αααααα
84.23$ - 157.98$
ααΎαβαα»αβααΈααααΆα
12.41Β αααΈααΆα USD
ααα ααα½αααΌαααααα
1.43Β ααΆα
α’αα»ααΆα P/E
42.50
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NASDAQ
ααααααΆαααΈααααΆα
Bloomberg
14 ααααβαα»α
S&P Dow Jones Makes No Changes to S&P 500 in Quarterly Rebalance
3.27%
1.03%
1.05%
CNBC
21 ααααβαα»α
Omada shares rise 21% in Nasdaq debut after health tech company's IPO
1.92%
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 572.60Β ααΆα | 11.12% |
α
αααΆαααααα·ααααα·ααΆα | 276.50Β ααΆα | 13.74% |
α
αααΌααα»ααα | 7.90Β ααΆα | -81.80% |
ααααΆααα
αααααα»ααα | 1.38 | -83.61% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 0.70 | -41.67% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 31.30Β ααΆα | -71.93% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 46.26% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 943.50Β ααΆα | -22.06% |
ααααααααα»α | 3.69Β αααΈααΆα | 6.20% |
ααΆαααα½ααα»αααααΌαααα»α | 1.15Β αααΈααΆα | 6.05% |
ααΌαβααααα»α | 2.54Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 98.97Β ααΆα | β |
ααααααααααΉαααααα
| 4.87 | β |
ααα
ααααααΎαααααα | 1.60% | β |
ααα
ααααααΎααΎααα»α | 1.94% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | 7.90Β ααΆα | -81.80% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 64.80Β ααΆα | -50.27% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | 14.20Β ααΆα | 125.82% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -117.90Β ααΆα | -268.67% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -38.90Β ααΆα | -126.79% |
ααα αΌαααΆα
αααααΆααααααα | 28.91Β ααΆα | -88.50% |
α’αααΈ
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
ααΆααααααΎαα‘αΎα
1992
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
1,800
